USA flag logo/image

An Official Website of the United States Government

Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93574
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA141754
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
IMMUNOMEDICS, INC.
300 The American Road Morris Plains, NJ 07950-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy
Agency: HHS
Contract: 2R44CA141754-02
Award Amount: $2,828,873.00
 

Abstract:

DESCRIPTION (provided by applicant): As a continuation of a successful Phase I SBIR, this Phase II application is directed towards the further development of a novel immunocytokine, named 20-2b, for improved therapy of B-cell lymphomas. In the United State s, there were 65,980 new cases of non-Hodgkin lymphoma (NHL) and 19,500 deaths from this disease in 2009. Of all B-cell NHL, 55% are of the DLBCL type, only half of which are curable. The remainder comprises indolent lymphomas (45%), none of which are cura ble. For 75% of all NHL patients newly diagnosed and a higher percentage of those alive at any time with evidence of disease, there remains a need for more effective treatments for these diseases, especially the incurable indolent types. Interferon-alpha-2 (IFNa2) is indicated for the therapy of a variety of hematopoietic and solid tumors. Combination therapy of NHL using IFNa2 and the anti-CD20 monoclonal antibody (MAb) rituximab is more effective than either agent as a monotherapy. However, the therapeuti c potential of IFNa2 has not been fully realized primarily due to its short circulating half-life and systemic toxicity. Fusion of IFNa2 to a MAb markedly increases its circulating half-life, allowing less frequent administration of a single agent at a con siderably lower dose than given for each agent in combination therapy. Targeting with an anti-CD20 MAb results in an increased and durable local concentration of IFNa2 at the sites of NHL while limiting its systemic concentration. This approach would signi ficantly limit or eliminate many side effects and may result in an efficacy that is far superior to what is achievable using combination therapy. 20-2b was generated using the Dock-and-Lock (DNL) method to comprise 4 IFNa2b groups site-specifically tethere d to the humanized anti-CD20 MAb, veltuzumab, for targeted delivery of IFNa2b to NHL. Successful product and process development, as well as extensive biochemical and biological characterizations of 20-2b were accomplished during Phase I. These very encour aging results reinforce Immunomedics commitment to the clinical investigation and ultimate commercialization of 20-2b. Initial clinical trials will be performed in relapsed/refractory indolent lymphoma, with additional expansion to other forms of NHL once these initial safety/efficacy studies are completed. To fulfill these clinical goals, this Phase II application will be concerned primarily with the finalization of the manufacturing process and the completion of regulatory requirements, which include qual ification of master cell banks, validation of the cGMP manufacturing process and production of cGMP lots of 20-2b sufficient for performing safety testing in Cynomolgus monkeys and initial clinical trials. Upon completion, an IND for Phase I clinical trial s will be submitted to FDA. Because the safety and efficacy of both IFNa2b and veltuzumab are well established from extensive clinical investigation, there is considerable potential for clinical and commercial success of 20-2b in NHL therapy. PUBLIC HEALTH RELEVANCE: The prototype construct investigated in this project, 20-2b, is a candidate therapeutic biologic agent for the treatment of B-cell malignancies including NHL and CLL, which may be refractory to the current front-line therapies. The lesso ns learned from this project may eventually lead to the development of additional MAb-IFNa for therapy of a variety of hematopoeitic and solid tumors.

Principal Investigator:

Edmund A. Rossi
9736051330
EROSSI@IMMUNOMEDICS.COM

Business Contact:

Chau Cheng
pparker@immunomedics.com
Small Business Information at Submission:

IMMUNOMEDICS, INC.
300 AMERICAN ROAD MORRIS PLAINS, NJ -

EIN/Tax ID: 161100936
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No